novo nordisk fda semaglutide has officially filed for approval of CagriSema, a powerful new once-weekly injection that combines a GLP-1 receptor agonist with an amylin analogue, setting the stage for the next major The FDA approved a pill

Reduces Glucagon Release: Glucagon is another hormone that raises blood sugar levels by signaling the liver to release stored sugar

For example, a study published in the journal Obesity found that participants taking semaglutide lost an average of 15% of their body weight over a year

Although patent 780 specifically claims the method of treating diabetes mellitus, it also discloses how the compounds, including tirzepatide, can be used to treat other indications, including obesity and increasing bone strength

Medicines in the semaglutide family (GLP-1 agonists) are being studied to see what role they might have in reducing the risk of other chronic problems such as heart disease, which often occur in tandem with obesity